1
/
의
1
Elabscience
SKU(재고 관리 코드):PKSV030405
Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active)
Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active)
Introducing the Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active), a cutting-edge product designed to address the urgent need for effective solutions in combating the SARS-CoV-2 virus. This meticulously engineered recombinant protein showcases exceptional quality and functionality, making it an invaluable asset in various research and diagnostic applications.
The Spike RBD (Receptor Binding Domain) of the SARS-CoV-2 virus plays a pivotal role in viral entry into host cells, making it a prime target for therapeutic interventions. Our Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active) is specifically designed to exhibit enhanced binding affinity, thereby facilitating comprehensive investigations into the virus-host interaction and aiding in the development of potential antiviral strategies.
Crafted with utmost precision, this recombinant protein is produced through advanced genetic engineering techniques, ensuring its utmost purity and consistency. The incorporation of the R408I mutation further enhances the protein's stability and functionality, enabling accurate and reliable experimental results.
The inclusion of the His Tag allows for facile purification and detection, streamlining laboratory workflows and expediting research processes. This feature, combined with the protein's inherent activity, empowers researchers to delve deeper into the intricate mechanisms of SARS-CoV-2, unraveling crucial insights that contribute to the global fight against the ongoing pandemic.
The Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active) is meticulously characterized through rigorous quality control measures, ensuring its compliance with the highest industry standards. Each batch is subjected to meticulous testing, guaranteeing its exceptional performance and reproducibility.
With its exceptional attributes and unwavering commitment to scientific excellence, the Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active) stands as an indispensable tool for researchers, clinicians, and diagnostic laboratories alike. Embrace this cutting-edge solution and unlock new frontiers in the battle against SARS-CoV-2, paving the way for a safer and healthier future.
The Spike RBD (Receptor Binding Domain) of the SARS-CoV-2 virus plays a pivotal role in viral entry into host cells, making it a prime target for therapeutic interventions. Our Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active) is specifically designed to exhibit enhanced binding affinity, thereby facilitating comprehensive investigations into the virus-host interaction and aiding in the development of potential antiviral strategies.
Crafted with utmost precision, this recombinant protein is produced through advanced genetic engineering techniques, ensuring its utmost purity and consistency. The incorporation of the R408I mutation further enhances the protein's stability and functionality, enabling accurate and reliable experimental results.
The inclusion of the His Tag allows for facile purification and detection, streamlining laboratory workflows and expediting research processes. This feature, combined with the protein's inherent activity, empowers researchers to delve deeper into the intricate mechanisms of SARS-CoV-2, unraveling crucial insights that contribute to the global fight against the ongoing pandemic.
The Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active) is meticulously characterized through rigorous quality control measures, ensuring its compliance with the highest industry standards. Each batch is subjected to meticulous testing, guaranteeing its exceptional performance and reproducibility.
With its exceptional attributes and unwavering commitment to scientific excellence, the Recombinant SARS-CoV-2 Spike RBD (R408I)(His Tag)(Active) stands as an indispensable tool for researchers, clinicians, and diagnostic laboratories alike. Embrace this cutting-edge solution and unlock new frontiers in the battle against SARS-CoV-2, paving the way for a safer and healthier future.
Share
